Marlio Charles Mosseri is 10% Owner at Nuvectis Pharma, Inc. (NVCT). They have made 26 open-market trades across 1 company since 2023, most recently 2026-06-30.
CIK 0001806384
26 open-market purchases totalling $12.1M since 2023, never a sale. Across 26 scored buys the stock is down 18.5% at ninety days, and 17.7 points behind the S&P over the same stretch.
26 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| NVCT | 3,186,576 | $59.3M |
Shares reported on the most recent Form 4, priced at the 2026-07-01 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 35% | 31% | 15% |
| Avg Move | -0.7% | -2.1% | -18.5% |
| Alpha | -1.2% | -2.8% | -17.7% |
| Scored | 26 | 26 | 26 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NVCT | BUY | 2026-06-30 | 2026-07-01 | $18.32 | $916K | -6.4% | +9.8% | +5.3% |
| NVCT | BUY | 2025-10-23 | 2025-10-29 | $6.21 | $1.6M | -10.3% | -7.8% | +29.2% |
| NVCT | BUY | 2025-06-20 | 2025-06-24 | $7.99 | $45K | -3.8% | -5.3% | -21.2% |
| NVCT | BUY | 2025-06-17 | 2025-06-20 | $8.06 | $495K | -7.2% | -1.5% | -21.0% |
| NVCT | BUY | 2025-05-12 | 2025-05-13 | $8.11 | $343K | +15.2% | +3.5% | -28.1% |
| NVCT | BUY | 2025-05-08 | 2025-05-12 | $8.93 | $423K | +19.7% | +6.3% | -26.2% |
| NVCT | BUY | 2025-05-06 | 2025-05-09 | $8.61 | $405K | +12.2% | -1.2% | -31.1% |
| NVCT | BUY | 2025-02-07 | 2025-02-11 | $5.00 | $1.2M | +15.4% | +30.9% | +31.4% |
| NVCT | BUY | 2024-12-12 | 2024-12-16 | $4.65 | $378K | +5.8% | +8.8% | +92.3% |
| NVCT | BUY | 2023-07-31 | 2023-08-01 | $13.88 | $12K | +10.5% | +3.3% | -39.6% |
| NVCT | BUY | 2023-07-28 | 2023-07-31 | $13.91 | $36K | +7.8% | +5.2% | -39.8% |
| NVCT | BUY | 2023-07-27 | 2023-07-28 | $13.98 | $22K | +7.1% | -1.7% | -36.3% |
| NVCT | BUY | 2023-07-26 | 2023-07-27 | $13.97 | $140K | +4.2% | -3.5% | -36.9% |
| NVCT | BUY | 2023-07-20 | 2023-07-24 | $14.44 | $197K | -0.3% | -0.7% | -38.1% |
| NVCT | BUY | 2023-07-19 | 2023-07-20 | $14.84 | $119K | -3.8% | +4.2% | -34.5% |
| NVCT | BUY | 2023-07-18 | 2023-07-19 | $14.84 | $272K | -7.7% | -2.0% | -37.4% |
| NVCT | BUY | 2023-07-12 | 2023-07-13 | $15.09 | $50K | -5.1% | -1.8% | -32.5% |
| NVCT | BUY | 2023-07-11 | 2023-07-12 | $15.36 | $154K | -6.1% | -1.2% | -30.6% |
| NVCT | BUY | 2023-07-07 | 2023-07-10 | $15.19 | $272K | -11.6% | -7.5% | -32.5% |
| NVCT | BUY | 2023-07-06 | 2023-07-07 | $15.01 | $48K | -5.8% | -5.3% | -29.4% |
| NVCT | BUY | 2023-07-05 | 2023-07-06 | $15.52 | $18K | -4.3% | -5.3% | -28.5% |
| NVCT | BUY | 2023-06-26 | 2023-06-27 | $16.46 | $552K | -3.3% | -15.7% | -17.8% |
| NVCT | BUY | 2023-06-23 | 2023-06-26 | $17.43 | $2.6M | -8.2% | -16.5% | -17.3% |
| NVCT | BUY | 2023-06-21 | 2023-06-23 | $17.72 | $464K | -10.3% | -14.0% | -19.1% |
| NVCT | BUY | 2023-06-16 | 2023-06-20 | $17.75 | $225K | -10.3% | -19.8% | -18.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.